Menu
Recruiting NCT06352203

Effect of Probiotics on the Intestinal Microbiota of Pediatric Patients

No phase Interventional Neurodevelopmental Disorders

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Probiotic, Placebo.
Who it may be relevant to
Registry conditions: Neurodevelopmental Disorders. Basic parameters: 3 years — 7 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Spain
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Randomized, Double-blind, Placebo-controlled Study to Evaluate the Modulating Effect of Probiotics on the Intestinal Microbiota of Pediatric Patients With Neurodevelopmental Disorders.

Overview

Numerous studies have described an altered gut microbiota composition (dysbiosis) in patients with neurodevelopmental disorders that can be correlated with their symptoms, especially gastrointestinal symptoms. An interventional, randomised, double-blind, placebo-controlled study will be conducted to investigate the effect of a probiotic supplement on the microbiota composition of children aged 3-7 years with neurodevelopmental issues. The duration of the study will be of 6 months approximately, including 6 months of product intake. Participants will be randomly assigned to one of the two study groups: control group with placebo administration or probiotic administration group.

Interventions

  • Dietary supplement Probiotic
    1 dose of the probiotic every 24 hours, for 6-months.
  • Dietary supplement Placebo
    1 dose of the placebo every 24 hours, for 6-months.

Primary outcome measures

  • Number of children with intestinal dysbiosis after 6 months of treatment. [Time frame: After 6 months of intervention.]

Eligibility criteria

Inclusion criteria

  • Children aged 3 to 7 years old.
  • Diagnosed with autism spectrum disorder, according to the clinical criteria of the "Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5)" and who meet criteria for ASD according to the ADOS-2 classification.
  • Presenting one or more gastrointestinal symptoms (constipation, diarrhoea, abnormal stools, painful defecation, abdominal pain, reflux, bloating, flatulence).
  • Written informed consent signed by the parent or legal guardian with express or tacit consent of the other parent.

Exclusion criteria

  • With intake of antibiotics in the last month.
  • With intake of probiotics in the last two weeks.
  • Diagnosed with short bowel syndrome or has undergone relevant surgery on the gastrointestinal tract.
  • Exhibiting a defect in the intestinal epithelial barrier (e.g. inflammatory bowel disease (IBD)).
  • Diagnosed with endocrinological diseases such as diabetes mellitus, hypo- and hyperthyroidism, Cushing's disease, Addison's disease, etc.
  • Having heart failure and a cardiac medical history (e.g. artificial heart valve, medical history of infective endocarditis, rheumatic fever, or cardiac malformation).
  • Congenital or acquired immunodeficiency.
  • Immunocompromised (e.g., cancer and/or transplant patients taking certain immunosuppressive drugs, patients with inherited diseases that affect or may affect the immune system).
  • Uncertainty on the part of the investigator about the willingness or ability of the minor's parents or legal guardian to comply with the requirements of the protocol.
  • With oral hyper sensitivity impairments that prevent the uptake of the study product.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Triple blind
Primary purpose
Treatment

Study locations

Spain · 1 center
  • Hospital Universitario Infantil Niño Jesús — Madrid

Identifiers

NCT: NCT06352203 · AUT/23.02

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗